Table 3

Net total incremental costs accrued through 100% detection of each high risk condition separately. 95% credible intervals obtained through probabilistic sensitivity analysis are shown in brackets

5 year horizon10 year horizon25 year horizon
Current care managementNICE guidelinesCurrent care managementNICE guidelinesCurrent care managementNICE guidelines
Hypertension£0.69b
(−£0.8b to £1.8b)
£2.9b
(−£1.1b to £5.1b)
−£0.05b
(−£3.8b to £2.2b)
£2.1b
(−£6.5b to £7.4b)
−£1.9b
(−£12.1b to £5.3b)
−£2.1b
(−£22.0b to £10.7b)
High cholesterol/ QRISK≥10%−£1.1b
(−4.4b to £0.7b)
−£1.1b
(−10.4b to £3.2b)
−£2.3b
(−£9.3b to £1.7b)
−£3.8b
(−£21.6b to £5.4b)
−£2.9b
(−£17.2b to £7.8b)
−£2.9b
(−£35.6b to £18.4b)
Diabetes£0.49b
(−£1.3b to £2.4b)
£2.6b
(−£1.2b to £6.2b)
−£1.2b
(−£6.8b to £3.4b)
£2.4b
(−£7.7b to £11.5b)
−£56.7b
(−£92.6b to −£29.9b)
−£49.3b
(−£98.5b to −£17.3)
NDH£2.2b
(£1.1b to £3.0b)
£3.6b
(£1.9b to £5.1b)
£2.1b
(−£0.8b to £4.4b)
£3.7b
(£0.4b to £6.5b)
£3.6b
(−£7.1b to £13.3b)
£4.4b
(−£4.1b to £17.6b)
AF£0.39b
(−£1.2b to £2.3b)
£1.1b
(−£1.7b to £5.9b)
£0.9b
(−£1.8b to £4.1b)
£2.1b
(−£2.6b to £9.5b)
£2.5b
(−£2.6b to £9.8b)
£4.7b
(−£4.1b to £17.6)
CKD−£0.32b
(−£1.3b to £0.3b)
−£1.4b
(−£4.3b to £0.5b)
−£0.53b
(−£2.4b to £0.9b)
−£2.1b
(−£6.8b to £1.2b)
−£0.42b
(−£4.7b to £3.4b)
−£1.8b
(−10.5b to £5.3b)
  • AF, atrial fibrillation; CKD, chronic kidney disease; NDH, non-diabetic hyperglycaemia; NICE, National Institute for Health and Care Excellence.